Literature DB >> 34252496

Cytomegalovirus infection in critically ill patients with COVID-19.

Takayuki Niitsu1, Takayuki Shiroyama2, Haruhiko Hirata1, Yoshimi Noda1, Yuichi Adachi1, Takatoshi Enomoto1, Reina Hara1, Saori Amiya1, Akinori Uchiyama3, Yoshito Takeda1, Atsushi Kumanogoh1.   

Abstract

Entities:  

Year:  2021        PMID： 34252496     DOI： 10.1016/j.jinf.2021.07.004

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  9 in total

1.  Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection.

Authors:  Scott Schoninger; Yanina Dubrovskaya; Kassandra Marsh; Diana Altshuler; Prithiv Prasad; Eddie Louie; Scott Weisenberg; Sarah Hochman; David Fridman; Polina Trachuk
Journal:  Open Forum Infect Dis       Date:  2022-06-10       Impact factor: 4.423

2.  CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients.

Authors:  Simone Weber; Victoria Kehl; Johanna Erber; Karolin I Wagner; Ana-Marija Jetzlsperger; Teresa Burrell; Kilian Schober; Philipp Schommers; Max Augustin; Claudia S Crowell; Markus Gerhard; Christof Winter; Andreas Moosmann; Christoph D Spinner; Ulrike Protzer; Dieter Hoffmann; Elvira D'Ippolito; Dirk H Busch
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

3.  Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis.

Authors:  Kentaro Shimizu; Haruhiko Hirata; Daijiro Kabata; Natsuko Tokuhira; Moe Koide; Akiko Ueda; Jotaro Tachino; Ayumi Shintani; Akinori Uchiyama; Yuji Fujino; Hiroshi Ogura
Journal:  J Infect Chemother       Date:  2021-12-31       Impact factor: 2.211

4.  Impact of adaptive natural killer cells, KLRC2 genotype and cytomegalovirus reactivation on late mortality in patients with severe COVID-19 lung disease.

Authors:  Sarita Rani Jaiswal; Jaganath Arunachalam; Ashutosh Bhardwaj; Ashraf Saifullah; Rohit Lakhchaura; Mayank Soni; Gitali Bhagawati; Suparno Chakrabarti
Journal:  Clin Transl Immunology       Date:  2022-01-11

5.  Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19.

Authors:  Yuji Yamamoto; Takayuki Shiroyama; Haruhiko Hirata; Tomoki Kuge; Kinnosuke Matsumoto; Midori Yoneda; Makoto Yamamoto; Akinori Uchiyama; Yoshito Takeda; Atsushi Kumanogoh
Journal:  J Med Virol       Date:  2021-11-03       Impact factor: 20.693

6.  RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies.

Authors:  Tamara Caniego-Casas; Laura Martínez-García; Marina Alonso-Riaño; David Pizarro; Irene Carretero-Barrio; Nilda Martínez-de-Castro; Ignacio Ruz-Caracuel; Raúl de Pablo; Ana Saiz; Rosa Nieto Royo; Ana Santiago; Marta Rosas; José L Rodríguez-Peralto; Belén Pérez-Mies; Juan C Galán; José Palacios
Journal:  Front Microbiol       Date:  2022-01-31       Impact factor: 5.640

Review 7.  How Immunosenescence and Inflammaging May Contribute to Hyperinflammatory Syndrome in COVID-19.

Authors:  Ludmila Müller; Svetlana Di Benedetto
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

8.  Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center.

Authors:  Ruei-Chang Huang; Chun-Hsiang Chiu; Hung-Sheng Shang; Cherng-Lih Perng; Tsung-Ta Chiang; Chun-Chou Tsai; Ching-Hsun Wang
Journal:  J Microbiol Immunol Infect       Date:  2022-08-17       Impact factor: 10.273

9.  A case-series of six autopsy cases of COVID-19 including three cases of cytomegalovirus coinfection.

Authors:  Jotaro Nakashima; Yuichiro Kadomatsu; Shingo Itagaki; Toshinori Otani; Takahiro Kiriu; Atsumi Matsunaga; Saya Munakata; Haruka Okada
Journal:  Pathol Int       Date:  2022-05-11       Impact factor: 2.121
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.